PharmaCyte Biotech's Novel Approach to Brain Cancer

BALTIMORE, April 9, 2015 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it in its entirety, please visit www.GoldmanResearch.com. 

In the article, analyst Rob Goldman discusses how the Company's approach to brain cancer by using Cannabinoids may be its most overlooked and most exciting offering.

"Ever since a 60 Minutes report on a novel, if not dangerous, approach to treating brain cancer was recently aired on CBS, the topic of brain cancer treatment has risen to the forefront of many in the oncology and scientific communities. Results have ranged from extraordinary to poor, but the concept of treating this deadly disease via out-of-the-box methods clearly has merit, as does the one promoted by PharmaCyte Biotech".

Goldman noted that, "The Company seeks to combine its Cell-in-a-Box® cellulose-based live cell encapsulation technology with constituents of Cannabis, known as cannabinoids, or cannabinoid-like compounds to develop unique treatments for difficult-to-treat and deadly forms of cancer, such as brain cancer.  Some cannabinoids are prodrugs that must be converted into their cancer-killing form.  These prodrugs will be used with the Cell-in-a-Box® technology in ways that optimize their anticancer properties while minimizing or even eliminating adverse side effects normally occurring with chemotherapy. This approach mirrors the Company's approach to pancreatic cancer, whereby results have proven very effective, thus far."

"In the laboratory, cannabinoids have shown effectiveness against glioma (a type of brain cancer),  and in mice, cannabinoids reduced tumor growth and spreading and were also shown to inhibit the growth of new blood vessels required for tumor growth.  In 2006, in a small, early-phase clinical trial, THC was shown to be beneficial for patients in treating glioblastoma multiforme, a severe and deadly type of brain cancer, when safe doses were used.  Given that cannabinoids have proven, in early testing, to break through the blood brain barrier, the use of cannabinoids in combination with PharmaCyte Biotech's Cell-in-a-Box® could emerge as the secret weapon to treat brain cancer."

"To that end, In May 2014 PharmaCyte Biotech entered into a research agreement with the University of Northern Colorado to perform initial research that will be necessary for the development of cannabinoid-based treatments for serious cancers.  The university is working to identify a cell type capable of converting cannabinoid-like prodrugs into their cancer-killing forms.  Once a satisfactory cell type is identified, the cells will be encapsulated using the Cell-in-a-Box® technology for use in combination with one or more cannabinoid prodrugs."  

Goldman believes that progress on this front in 2015 is likely to serve as a major catalyst for a boost in the Company's standing and market value as PharmaCyte Biotech emerges as a formidable player in the treatment of brain cancer, which is a market worth hundreds of millions of dollars annually.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was recently compensated by a third party in the amount of $4000 for investment research services and has been compensated $2500 for the publication of a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
[email protected]

SOURCE Goldman Small Cap Research

Related Links

http://www.PharmaCyteBiotech.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED